Aura Biosciences (AURA) Preferred Stock Liabilities (2020 - 2021)
Aura Biosciences (AURA) posted Preferred Stock Liabilities of $11.7 million for Q3 2021, down 79.24% on a QoQ basis from $56.6 million in Q2 2021, and up 248.75% year-over-year from $3.4 million in Q3 2020.
Aura Biosciences (AURA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Aura Biosciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $11.7 million for Q3 2021.
- Quarterly Preferred Stock Liabilities rose 248.75% year-over-year to $11.7 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $11.7 million (up 248.75% YoY) and the FY2020 annual result came in at $128.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $11.7 million for Q3 2021 at Aura Biosciences, down from $56.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $128.1 million in Q4 2020 and bottomed at $3.4 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aura Biosciences | 485.62 Mn | 400.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 11.75 Mn |
| Jun 30, 2021 | 56.58 Mn |
| Mar 31, 2021 | 80.25 Mn |
| Dec 31, 2020 | 128.08 Mn |
| Sep 30, 2020 | 3.37 Mn |